on ABIVAX (EPA:ABVX)
Abivax publishes its 2024 financial reports
Abivax SA, a Paris-based biotechnology company, filed its Universal Registration Document with the AMF and its Annual Report with the SEC on March 24, 2025. These filings include the 2024 annual financial report, as well as the management and corporate governance report, accompanied by the auditors' reports. Abivax, listed on Euronext Paris and Nasdaq, focuses on developing treatments that exploit the body's natural regulatory mechanisms for chronic inflammatory diseases. The documents are available on the Abivax, AMF, and SEC websites.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABIVAX news